Sana Biotechnology Revenue and Competitors

Seattle, WA USA

Location

$700M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Sana Biotechnology's estimated annual revenue is currently $71.3M per year.(i)
  • Sana Biotechnology's estimated revenue per employee is $163,908
  • Sana Biotechnology's total funding is $700M.
  • Sana Biotechnology's current valuation is $2.1B. (January 2022)

Employee Data

  • Sana Biotechnology has 435 Employees.(i)
  • Sana Biotechnology grew their employee count by -24% last year.

Sana Biotechnology's People

NameTitleEmail/Phone
1
President and CEOReveal Email/Phone
2
Chief People OfficerReveal Email/Phone
3
VP, Head BiometricsReveal Email/Phone
4
VP, Deputy General Counsel and Assistant SecretaryReveal Email/Phone
5
VP, Viral Vector OperationsReveal Email/Phone
6
VP, LegalReveal Email/Phone
7
Head Tech Ops - ITReveal Email/Phone
8
SVP, Head Regulatory Affairs & StrategyReveal Email/Phone
9
SVP, Head Technical OperationsReveal Email/Phone
10
VP, Head Analytical Development and Quality ControlReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.9M60%N/AN/A
#2
$0.9M60%N/AN/A
#3
$5.1M336%N/AN/A
#4
$5.7M3742%N/AN/A
#5
$1.4M18-10%N/AN/A
#6
$3.7M48-21%$16MN/A
#7
$1.1M70%N/AN/A
#8
$0.8M5-81%N/AN/A
#9
$2.5M16-27%N/AN/A
#10
$0.8M5-17%N/AN/A
Add Company

What Is Sana Biotechnology?

Sana Biotechnology is focused on utilizing engineered cells as medicines for patients. The ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades. Sana is building differentiated capabilities across the spectrum of cell and gene therapy. Three aspirations drive Sana as we look to discover treatments for patients with poor outcomes or currently untreatable diseases. The first is the ability to repair and control the genes in any cell in the body. We are advancing novel delivery technologies with the goal of being able to deliver any payload to any cell in a specific, predictable, and repeatable manner, paving the way for next-generation in vivo gene therapy. Next is the ability to differentiate pluripotent stem cells ex vivo into immune-cloaked functional cells with the aspiration of being able to replace any missing or damaged cells in the body. Last is a belief we can enable broader access to our therapies through focusing on scalable manufacturing solutions, the cost of manufacturing, and aligning with key stakeholders. Sana launched in early 2019 and has approximately two hundred employees in Seattle, Cambridge, and South San Francisco. In 2019, we raised capital to enable our broad vision, began to acquire technology and establish an IP estate across cell and gene therapy, and made significant progress validating our cell and gene therapy platforms. Growing from this foundation, we intend to push forward our platforms and product pipeline in 2020 and beyond.

keywords:N/A

$700M

Total Funding

435

Number of Employees

$71.3M

Revenue (est)

-24%

Employee Growth %

$2.1B

Valuation

N/A

Accelerator

Sana Biotechnology News

2022-04-06 - Sana Biotechnology (NASDAQ:SANA) Cut to "Strong Sell" at Zacks Investment Research

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo...

2022-03-30 - Sana On Track to Remove Barriers for Cell & Gene Therapy

A Sana scientist works in the lab/Photo courtesy of Sana Biotechnology. One of the most important transformations of 21st-century medicine...

2022-03-22 - As Sana Biotechnology, Inc. (NASDAQ:SANA) gains 17%, insiders who bought last year may be wishing they had bet higher

Sana Biotechnology Insider Transactions Over The Last Year. In fact, the recent purchase by Patrick Yang was the biggest purchase of Sana...

2021-07-15 - Catal­ent lands 2 new part­ner­ships, in­clud­ing for glioblas­toma drug; US drops $153M in­to pan­dem­ic pre­pared­ness

A unicorn multiple times over, Sana Biotechnology hit Nasdaq running in February with its next-gen cell therapies still months away from the clinic. Now, Sana is looking to the future once again and clearing out some elbow room for its manufacturing team. Sana has entered a long-term lease to d ...

2021-03-02 - How SPACs are changing the IPO game: Equity ownership of founders a big consideration

SPACs are hot right now, and one of the reasons is they can keep more equity in the hands of founders. (GeekWire Illustration / Canva Image, adrian825) A few weeks ago, a longtime GeekWire reader sent a note expressing shock that Sana Biotechnology co-founder and CEO Steve Harr only owned 4.9% ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$98.3M437N/AN/A
#2
$87.4M43727%N/A
#3
$137.1M43754%N/A
#4
$159.9M441N/AN/A
#5
$99.5M44215%N/A